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Hypoestoxide reduces neuroinflammation
and α-synuclein accumulation in a mouse
model of Parkinson’s disease
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Howard Cottam3,4 and Eliezer Masliah1,2*
Abstract
Background: Deposition of α-synuclein and neuroinflammation are key pathological features of Parkinson’s disease
(PD). There is no cure for the disease; however, targeting the pathological features might be available to modulate
the disease onset and progression. Hypoestoxide (HE) has been demonstrated as a NF-κB modulator, thereby acting
as a potential anti-inflammatory and anti-cancer drug.
Methods: In order to assess the effect of HE in a mouse model of PD, mThy1-α-syn transgenic mice received
intraperitoneal (IP) injections of either vehicle or HE (5 mg/kg) daily for 4 weeks.
Results: Treatment of HE decreased microgliosis, astrogliosis, and pro-inflammatory cytokine gene expression in
α-syn transgenic mice. HE administration also prevented the loss of dopaminergic neurons and ameliorated motor
behavioral deficits in the α-syn transgenic mice, and α-synuclein pathology was significantly reduced by treatment of
HE. In addition, increased levels of nuclear phosphorylated NF-κB in the frontal cortex of α-syn transgenic mice were
significantly reduced by HE administration.
Conclusions: These results support the therapeutic potential of HE for PD and other α-synuclein-related diseases.
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Background
Intraneuronal Lewy bodies (LBs) and Lewy neurites
(LNs) are key pathological features of Parkinson’s disease
(PD) [1]. α-synuclein is a small neuronal protein (140
amino acids), and the pathological amyloid fibrils are a
major component of LBs and LNs [2]. While the physio-
logical functions of α-synuclein are still unclear, studies
have suggested its roles in neuroplasticity and synaptic
vesicle recycling [2]. Furthermore, accumulating evidence
has demonstrated that abnormal deposition of α-synuclein
is not only a pathological feature but also plays critical
roles in the onset and progression of diseases [3].
In addition to α-synuclein deposits, neuroinflamma-
tion is another pathological feature of PD [4]. For ex-
ample, accumulations of reactive microglia have been
found in the brains of PD patients, and elevated levels of
inflammatory cytokines, such as TNFα and IL6 have
been detected in the CSF and plasma of PD patients [5].
In addition, studies have shown that neuroinflammation
is not only a pathological feature but also plays critical
roles in neurodegeneration. Administration of anti-
inflammatory drugs prevented dopamine neuronal de-
generation in substantia nigra (SN) of toxicant-induced
animal models of PD [6]. Epidemiological studies have
suggested that administration of non-steroidal anti-
inflammatory drugs reduce the risk for PD [7–9] sug-
gesting that reducing or preventing inflammation may
reduce the risk of PD.
Microglia, a brain resident immune cell, plays a central
role in the process of neuroinflammation. Microglia
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could be activated by various types of stimuli resulting
in neuroinflammation, including systemic inflammation,
brain injury, and ischemia [10]. Recent studies have also
showed that extracellular α-synuclein can also induce
activation of microglia. Exposure to various forms of
recombinant α-synuclein can induce activation of micro-
glia [3]. In our previous study, we demonstrated that
neuron-released oligomeric forms of α-synuclein-induced
microglia activation via interaction with TLR2 and β1-
integrin on the surface of microglia [8, 11].
Although it is well established that the outcome of
chronic neuroinflammation is neurodegeneration [6], re-
cent studies have also suggested the roles of neuroin-
flammation in the deposition and accumulation of
amyloid protein aggregates in the brain. For example,
neuroinflammation is induced by systemic administra-
tion of lipopolysaccharide (LPS)-induced accumulation
of amyloid-β in hippocampus of non-transgenic (non-tg)
mice [12, 13]. Similarly, intraperitoneal injection of LPS
increased accumulation of α-synuclein aggregates in
substantia nigra of both non-tg and α-synuclein trans-
genic (α-syn-tg) mice [14]. Furthermore, inhibition of
neuroinflammatory enzymes, such as NADPH oxidase
and iNOS decreased nigral α-synuclein deposition in α-
syn-tg mice [15] once again suggesting that blocking or
preventing inflammation may prevent PD pathology.
Hypoestoxide (HE) is a natural diterpene isolated from
the shrub Hypoestes rosea (Acanthaceae) [16]. Studies
have demonstrated that HE may modulate the activity of
NF-κB through IκB kinase inhibition [16]. Thereby, HE
has been suggested as a potential anti-inflammatory and
anti-cancer drug [16, 17]. The polar surface area for HE
is 68.4 Å2 which is considered very good for blood brain
barrier penetration. Therefore, we examined the potency
of HE as an anti-neuroinflammatory drug for PD using a
mouse model. In conclusion, administration of HE ame-
liorates neuroinflammation, neurodegeneration, and be-
havioral defects in a PD mouse model via modulation of
NF-κB activity, thus supporting a role for HE as an anti-
inflammatory drug for the treatment of PD.
Methods
Antibodies and chemicals
The protease and phosphatase inhibitor cocktails were
purchased from Sigma-Aldrich (St Louis, MO). Hypoest-
oxide was obtained from Immune Modulation, Inc.
(Bloomington, CA). The following antibodies were used:
α-synuclein (Syn-1; BD Bioscience, San Diego, CA);
TNFα, glial fibrillary acidic protein (GFAP) (GA5), TH,
and NeuN (Millipore, County Cork, Ireland); β-actin
(Sigma-Aldrich, St Louis, MO); NF-κB p65 and phospho-
NF-κB p65 (Cell signaling, Beverly, MA); IL-1β and IL6
(Abcam, Cambridge, MA); α-synuclein (CT, Syn105) [18];
α-synuclein (syn211) (Life Technologies, Grand Island,
NY); and Iba-1 (Wako, Richimond, VA).
Animal treatment and behavioral analysis
Mice overexpressing human α-synuclein under mThy1
promoter (α-syn-tg) were used for this study because
mice develop behavioral motor deficits, axonal path-
ology, and accumulation of α-synuclein in cortical and
subcortical regions, thus mimicking PD [19–21]. The
procedure for intraperitoneal injection has been de-
scribed elsewhere [22]. Briefly, 5-month-old non-tg and
α-syn-tg female mice were injected intraperitoneally (IP)
with either vehicle (40 % captisol) or hypoestoxide
(5 mg/kg) daily for 4 weeks. The right hemibrains were
post-fixed in phosphate-buffered 4 % PFA at 4 °C for
neuropathological analysis, while the left hemibrains
were snap-frozen and stored at −70 °C for subsequent
protein and messenger NA (mRNA) analysis. All animal
procedures were approved by the UCSD Institutional
Animal Care and Use Committee.
Following treatment, animals were assessed for gait
and coordination using the open field and the round
beam tests. As previously described [23], total activity
was calculated as total beam breaks in 10 min. The im-
pairment of gait and balance was accessed by round
beam analysis. Three consecutive trials of 1 min each
were run in 1 day. The numbers of foot slippages and
distance traveled were recorded. The total errors on the
beam were calculated as foot slips/distance traveled.
Immunohistochemistry and immunofluorescence and
neuropathological analysis
The procedures for immunohistochemical, immuno-
fluorescence, and neuropathological analysis have been
described elsewhere [22, 24]. Briefly, blind-coded sagittal
brain sections were incubated with primary antibodies at
4 °C for overnight. The next day, sections were incu-
bated with either biotinylated- or FITC-conjugated sec-
ondary antibodies and detected with avidin D-HRP HRP
(ABC elite, Vector Laboratories, Burlingame, CA) and
with Tyramide Signal Amplification Direct system
(PerkinElmer, Waltham, MA), respectively.
To determine the neuroinflammation, neurodegenera-
tion, accumulation of α-synuclein, and NF-κB activation,
we stained brain sections with Iba-1, GFAP, TNFα, IL-
1β, IL6, human α-synuclein, NF-κB, and phosphorylated
NF-κB antibodies, respectively. Sections were imaged by
Olympus BX41 microscope. All immunoreactivity levels
were determined by optical density analysis using Image
Quant 1.43 program (NIH) except the immunoreactivity
of Iba-1. The cell numbers of Iba-1-positive cells were
determined per field (230 μm× 184 μm) of each animal
based on cell body recognition using Image Quant 1.43
program (NIH).
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Preparation of tissue extract and Western blot analysis
The procedures for tissue extract preparation and Western
blot analysis have been described elsewhere [25]. Briefly,
brain homogenates were prepared in the lysis buffer to
separate sodium dodecyl sulfate (SDS)-soluble and SDS-
insoluble fractions. Chemiluminescence detection and ana-
lysis were performed using Versadoc XL imaging apparatus
and Quantity One (Bio-rad, Hercules, CA).
Quantitative polymerase chain reaction
The procedure for quantitative polymerase chain reac-
tion (qPCR) has been described elsewhere [23]. Briefly,
total mRNA was extracted from the mice frontal cortex
using RNeasy Lipid mini kit (Qiagen, Germantown,
MD) and reverse transcribed using SuperScript VILO
cDNA synthesis kit (Life Technologies), respectively.
Quantitative real-time PCR was performed using Taq-
Man® Fast Advanced Master Mix (Life Technologies)
according to manufacturer’s instruction with gene-
specific primers obtained from Life Technologies, such
as TNFα (Mm00443258_m1), IL6 (Mm00446190_m1), IL-
1β (Mm00434228_m1), and β-actin (Mm00607939_s1).
Amplification of DNA products was measured by the
StepOnePlus real-time PCR system (Applied Biosystems,
Carlsbad, CA). Relative mRNA levels were calculated
according to the 2-exp (ΔΔCt) method. All ΔCT values
were normalized to β-actin.
Statistical analysis
GraphPad Prism (GraphPad Software, San Diego, CA)
was used for all statistical analysis. All data are presented
as means ± s.e.m. All data were analyzed for statistical
significance by using either unpaired t test or two-way
ANOVA (general linear model) followed by Bonferroni’s
multiple comparison post-test.
Results
Administration of HE decreases neuroinflammation in a
mouse model of PD
Neuroinflammation is a key pathological feature in PD
that is recapitulated in the mThy-1α-synuclein trans-
genic (α-syn-tg) mouse model of PD [18, 23]. In order to
determine if neuroinflammation could be ameliorated,
we administered HE (5 mg/kg) through intraperitoneal
injection (IP) to the α-syn-tg mice daily for 4 weeks.
Analysis of the numbers of brain immune cells, such as
Iba-1-positive microglia and GFAP-positive astrocytes
were significantly increased in the neocortex of α-syn-tg
mice (Fig. 1). Interestingly, administration of HE signifi-
cantly decreased the numbers of microglial cells and
the levels of astrogliosis in the neocortex in α-syn-tg
mice to levels similar to those in non-tg mice (Fig. 1a,
b, d, and e). In addition to a decrease in overall num-
bers of immune cells in the α-syn-tg mice, we observed
a decrease in the numbers of branches per glial cell
(Fig. 1a, c, d, and f ) [26]. A positive interactive effect of
HE treatment on Iba-1 optical density (Finteraction (1, 16) =
80.48, p < 0.0001), numbers of microglia branches (Finteraction
(1, 16) = 83.25, p < 0.0001), GFAP optical density (Finteraction (1,
16) = 15.88, p= 0.0011), and numbers of astroglial branches
(Finteraction (1, 16) = 4.04, p= 0.0616) was confirmed by two-
way ANOVA.
To verify our observation, we analyzed the levels of
pro-inflammatory cytokines using immunohistochemical
analysis and gene expression analysis (Fig. 2). The levels
of TNFα, IL-1ß, and IL6 were increased in α-syn-tg mice
compared to non-tg mice (Fig. 2a–d). In contrast, treat-
ment of HE significantly reduced the levels of these pro-
inflammatory cytokines in the neocortex of α-syn-tg
mice (Fig. 2a–d). A positive interactive effect of HE
treatment on the levels of TNFα (Finteraction (1, 16) =
12.34, p = 0.0029), IL-1β (Finteraction (1, 16) = 11.58, p =
0.0036), and IL6 (Finteraction (1, 16) = 31.06, p < 0.0001) was
confirmed by two-way ANOVA. In addition, quantitative
gene expression analysis showed the mRNA levels of
TNFα, IL-1β, and IL6 were clearly decreased by HE
administration in the neocortex of α-syn-tg mice
(Fig. 2e–g). A positive interactive effect of HE treatment
on the mRNA levels of TNFα (Finteraction (1, 16) = 15.78,
p = 0.0019), IL-1β (Finteraction (1, 16) = 11.65, p = 0.0051),
and IL6 (Finteraction (1, 16) = 6.40, p = 0.0264) was con-
firmed by two-way ANOVA. Together, these results
suggest that administration of HE inhibits activation of
microglia and astrocytes, thereby reducing the produc-
tion of pro-inflammatory cytokines in a mouse model
of PD.
Amelioration of neurodegeneration and behavioral defect
by HE administration in a mouse model of PD
Neuroinflammation is one of the well-known causes
of neurodegeneration [3]. Since the levels of pro-
inflammatory cytokines were significantly decreased
by HE administration in α-syn-tg mice, we hypothe-
sized that administration of HE would prevent neuro-
degeneration and behavioral deficit through inhibition
of neuroinflammation in α-syn-tg mice. To verify the
hypothesis, we performed neurodegeneration analysis
and behavioral tests using non-tg and α-syn-tg mice
treated with either vehicle or HE (Fig. 3). Neuronal
overexpression of human α-synuclein resulted in the
loss of TH-positive striatal fibers in α-syn-tg mice
while the numbers of nigral TH-positive cells were
not altered by α-synuclein expression (Fig. 3a–c).
However, administration of HE significantly de-
creased the loss of TH-positive striatal fibers in α-
syn-tg mice (Fig. 3a, b). A positive interactive effect of HE
treatment on the level of TH-positive striatal fibers
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(Finteraction (1, 16) = 5.12, p = 0.038) was confirmed by two-
way ANOVA.
To investigate the effect of HE on the anxiety-like be-
havior and motor behavior deficit in α-syn-tg mice, we
performed open field and round beam tests, respect-
ively (Fig. 3d, e). α-syn-tg mice showed a significant in-
crease of the beam break numbers and the total round
beam errors compared to non-tg control mice. Treat-
ment of α-syn-tg mice with HE reduced these errors to
levels observed in non-tg mice (Fig. 3d, e). A positive
interactive effect of HE treatment on the beam break
numbers (Finteraction (1, 16) = 15.61, p = 0.0011) and
total round beam errors (Finteraction (1, 16) = 8.58, p =
0.0098) was confirmed by two-way ANOVA. Taken
together, these results suggest that administration of
HE prevents neurodegeneration and ameliorates be-
havioral defect in a mouse model of PD.
Administration of hypoestoxide results in reduced
neuronal α-synuclein accumulation in a mouse model
of PD
To determine if the behavioral improvements observed
in the α-syn-tg mice were related to alterations of α-
synuclein pathology, we performed immunohistochemi-
cal analysis for α-synuclein with brain sections from
non-tg and α-syn-tg mice treated with either vehicle or
HE. Immunohistochemical analysis showed overexpres-
sion of α-synuclein in neurons and the neuropil of α-
syn-tg mice (Fig. 4a–e). Surprisingly, administration of
HE significantly decreased the levels of α-synuclein in
neurons and neuropil in α-syn-tg mice (Fig. 4a–e). A
positive interactive effect of HE treatment on the optical
density of α-synuclein (frontal cortex, Finteraction (1, 16) =
30.74, p < 0.0001; hippocampus, Finteraction (1, 16) = 13.66,
p = 0.0020; striatum, Finteraction (1, 16) = 7.19, p = 0.0164)
Fig. 1 Hypoestoxide reduces neuroinflammation in a mouse model of PD. Immunohistochemical analysis of Iba-1 and GFAP in neocortex of non-tg and
α-syn-tg mice injected with either vehicle or hypoestoxide. a Immunoreactivity against Iba-1 was analyzed in neocortex of the brains. b, c The numbers
of Iba-1-positive cells (b) and the average numbers of branches per Iba-1-positive cell (c) (n= 5 per each group; two-way ANOVA, Bonferroni’s multiple
comparison post-test; ***p< 0.001). Error bars represent ±SEM. d Immunoreactivity against GFAP was analyzed in neocortex of the brains. e, f Optical
density analysis of GFAP immunoreactivity (e) and the average numbers of branches per GFAP-positive cell (f) (n= 5 per each group; two-way ANOVA,
Bonferroni’s multiple comparison post-test; *p< 0.05, **p< 0.01, ***p< 0.001). Error bars represent ±SEM. Scale bars = 100 μm (low magnification) and
20 μm (high magnification)
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was confirmed by two-way ANOVA. To confirm our ob-
servations, we performed immunofluorescence analysis
with human α-synuclein-specific antibodies (Additional
file 1). Immunoreactivity against human α-synuclein was
not detected in the frontal cortex of non-tg mice, but it
was highly detected in the frontal cortex of α-syn-tg
mice (Additional file 1a, b). Similar to results from the
immunohistochemical analysis, the level of human α-
synuclein immunoreactivity was significantly decreased
by HE administration in the frontal cortex of α-syn-tg
mice (Additional file 1a, b). Recent evidence suggests the
C-terminal fragments of α-synuclein are particularly
neurotoxic [18]. To determine if the administration of
HE affected the accumulation of these C-terminal frag-
ments, we used an antibody that specifically recognizes
the C-terminus of human α-synuclein. Immunoreactivity
against C-terminus human α-synuclein was also signifi-
cantly decreased by HE administration in the frontal
cortex of α-syn-tg mice (Additional file 1c, d).
To verify our findings, we performed biochemical ana-
lysis (Fig. 4f, g). Brain homogenates were separated into
SDS-soluble and SDS-insoluble factions, and analyzed
by immunoblot analysis. Interestingly, the levels of α-
synuclein in SDS-soluble fractions from α-syn-tg mice
were not affected by HE administration (Fig. 4f, g). How-
ever, the levels of SDS-insoluble α-synuclein were
significantly decreased in the brain homogenates from
HE-administrated α-syn-tg mice (Fig. 4f, g). A positive
interactive effect of HE treatment on the level of SDS-
insoluble α-synuclein (Finteraction (1, 16) = 8.68, p = 0.0095)
was confirmed by two-way ANOVA. Taken together,
these results suggest that administration of HE re-
duces the accumulation of α-synuclein in a mouse
model of PD.
HE modulates neuroinflammation via inhibition of NF-κB
activity in a mouse model of PD
Previous work suggests that HE modulated the activity
of NF-κB, a key immune response signaling mediator,
through inhibition of IκB kinase in immune cells [16].
Therefore, we investigated the alteration of NF-κB ac-
tivity in the neocortex of non-tg and α-syn-tg mice that
received either vehicle or HE. Immunofluorescence
analysis showed that total levels of NF-κB were not
Fig. 2 Hypoestoxide reduces pro-inflammatory cytokines in the brain of α-syn-tg mice. a–d Immunofluorescence or immunohistochemical analysis of
TNFα, IL-1β, and IL6 in the neocortex of non-tg and α-syn-tg mice treated with either vehicle or hypoestoxide. a Representative images. b–d Quantitative
analysis of fluorescence intensities of TNFα (b), IL-1β (c), and IL6 (d) stainings were analyzed in the neocortex of the brains (n = 5 per each
group; two-way ANOVA, Bonferroni’s multiple comparison post-test; **p < 0.01, ***p < 0.001). Error bars represent ±SEM. e–g Quantitative real-
time PCR analysis of expression levels of TNFα (e), IL6 (f), and IL-1β (g) in the neocortex of mice presented as levels over β-actin (n = 4 per
each group; two-way ANOVA, Bonferroni’s multiple comparison post-test; **p < 0.01, ***p < 0.001). Error bars represent ±SEM. Scale bar = 20 μm
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changed by HE administration in the neocortex of non-
tg or α-syn-tg mice (Fig. 5a, b). However, the level of
immunoreactivity against phosphorylated NF-κB, the
activated form of NF-κB, was highly elevated (fourfold)
in the neocortex of α-syn-tg mice (Fig. 5a, c). In
addition, the elevated level of phosphorylated NF-κB
was significantly decreased by administration of HE in
the neocortex of α-syn-tg mice to levels observed in
non-tg mice (Fig. 5a, c). A positive interactive effect of
HE treatment on the immunoreactivity of phosphory-
lated NF-κB (Finteraction (1, 16) = 27.70, p < 0.0001) was
confirmed by two-way ANOVA. To verify our findings,
we performed biochemical analysis using brain homog-
enates from the cortex of non-tg and α-syn-tg mice
(Fig. 5d–f ). Brain homogenates were separated into
cytosolic and nuclear fractions by centrifugation, and
each fraction was analyzed by Western blot analysis.
Total levels of NF-κB were not altered by HE administra-
tion in non-tg and α-syn-tg mice (Fig. 5d, e). However, the
level of phosphorylated NF-κB was significantly increased
only in nuclear fraction from α-syn-tg mice brain homog-
enates (Fig. 5d, f ). Similar to results observed by immuno-
fluorescence, the level of phosphorylated NF-κB was
significantly reduced by HE administration in α-syn-tg
mice (Fig. 5d, f ). A positive interactive effect of HE
treatment on the level of phosphorylated NF-κB (Fin-
teraction (1, 16) = 11.55, p = 0.0037) was confirmed by
two-way ANOVA. Taken together, these results sug-
gest that administration of HE decreases neuroinflam-
mation through modulation of NF-κB activity in a
mouse model of PD.
Discussion
Previous studies have suggested an anti-inflammatory ef-
fect of HE, so we examined the potential for HE as an
anti-neuroinflammatory drug in the pathogenesis of PD
[16]. The levels of cytokine expression and the number
of reactive glial cells were significantly reduced by HE
administration in a model of PD. In addition, adminis-
tration of HE prevented neurodegeneration in a mouse
model of PD. The loss of TH-positive neurons was sig-
nificantly decreased by administration of HE in α-syn-tg
mice. Behavioral defect also has been ameliorated by HE
administration in α-syn-tg mice. Furthermore, we
demonstrated that HE inhibits the activity of NF-κB
which results in the decrease of neuroinflammation in
α-syn-tg mice.
Neuroinflammation is a typical pathological feature of
PD playing a critical role in disease onset and progres-
sion [3, 4]. Recent studies have also suggested that
Fig. 3 Hypoestoxide ameliorates neurodegeneration and behavioral deficits in α-syn-tg mice. a–c Immunohistochemical analysis of TH in the
striatum and substantia nigra (S.Nigra) of non-tg and α-syn-tg mice treated with either vehicle or hypoestoxide. a Representative images of
striatum. b The levels of dopaminergic fiber in striatum were analyzed by optical density quantification (n = 5 per each group; two-way ANOVA,
Bonferroni’s multiple comparison post-test; *p < 0.05, **p < 0.01). Error bars represent ±SEM. c Stereological analysis of TH-positive cells in S. Nigra.
d, e Motor behavioral analysis of non-tg and α-syn-tg mice. Total activity from open field analysis (d) and the numbers of slippages from round
beam test (e) were recorded (n = 5 per each group; two-way ANOVA, Bonferroni’s multiple comparison post-test; *p < 0.05, ***p < 0.001). Error bars
represent ±SEM. Scale bars = 250 μm (a, upper panel) and 25 μm (a, lower panel)
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extracellular α-synuclein is a strong inducer of neuroin-
flammation [8, 27]. Neurons endogenously release α-
synuclein via unconventional exocytosis, and this secre-
tion could be modulated by multiple factors including
genetic defects, oxidative modification of α-synuclein,
mitochondrial dysfunction, and autophagy inhibition
[28–32]. Previous studies have shown that exposure to
various forms of recombinant α-synuclein induces
microglia activation [25, 33–35]. In addition, we have
demonstrated that oligomeric forms of neuron-released
α-synuclein interact with TLR2 and β1-integrin on the
surface of microglia, thereby inducing pro-inflammatory
responses [8, 11]. Thus, in PD and other synucleinopathies,
reducing neuroinflammation may be a target for thera-
peutic intervention.
Intraneuronal accumulations of α-synuclein aggregates
are typical pathological features of PD, and studies have
demonstrated that these deposits are not only patho-
logical but also play a critical role in the onset and de-
velopment of PD. Recent studies have shown that
neuronal accumulation of α-synuclein can be affected by
multiple intra- and extra-neuronal factors, including
genetic defects, dysfunction of protein quality control
systems, secondary structural alterations, and exposure
to environmental toxicants [2, 24]. In addition, neuroin-
flammation has been suggested as a promotable factor
Fig. 4 Hypoestoxide reduces deposition of α-synuclein in a mouse model of PD. a Representative immunohistochemical staining of α-synuclein
in the frontal cortex, hippocampus, and striatum. b Optical density analysis for α-synuclein-positive neuropil in the frontal cortex (n = 5 per each
group; two-way ANOVA, Bonferroni’s multiple comparison post-test; ***p < 0.001). Error bars represent ±SEM. c The numbers of α-synuclein-
positive cells in the frontal cortex. d, e Optical density analysis of immunoreactivity of α-synuclein in the hippocampus (d) and in the striatum (e)
(n = 5 per each group; two-way ANOVA, Bonferroni’s multiple comparison post-test; **p < 0.01, ***p < 0.001). Error bars represent ±SEM. f, g
Biochemical analysis of SDS-soluble (f) and SDS-insoluble (g) fractions from the frontal cortex for α-synuclein (n = 5 per each group; two-way
ANOVA, Bonferroni’s multiple comparison post-test; **p < 0.01, ***p < 0.001). Error bars represent ±SEM. Scale bars = 250 μm (low magnification)
and 25 μm (high magnification)
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for α-synuclein aggregates in neurons [3]. In this study,
we observed that administration of HE reduced the
neuronal accumulation of α-synuclein in a model of PD.
Since the levels of α-synuclein mRNA were not affected
by administration of HE (data not shown), we speculate
that activation of the intraneuronal autophagy process
can be regulated by neuroinflammation.
We still do not know the mechanism by which
microglia-mediated neuroinflammation affects neuronal
accumulation of α-synuclein aggregates. However, re-
cent studies have shown that some pro-inflammatory
cytokines inhibit autophagy, an efficient intracellular
process for α-synuclein elimination [2, 36]. For example,
IL-10 inhibits starvation-induced, rapamycin-induced,
and lipopolysaccharide-induced autophagy in murine
macrophages [37–39]. In addition, IL-4 and IL-13
inhibit both starvation-induced and IFN-γ-induced
autophagosome formations in human and murine
macrophages [40]. These observations suggest that cyto-
kines from activated microglia may inhibit the autoph-
agy process of neighboring neurons in the brain,
thereby resulting in a neuronal α-synuclein accumula-
tion. Considering the previous results together with our
current study, we speculate that administration of HE
decreases neuronal accumulation of α-synuclein via re-
duction of neuroinflammation in a model of PD leading
to increased autophagic degradation of α-synuclein.
Conclusions
In conclusion, our work suggests that administration of
HE modulates the activity of NF-κB in a model of PD;
therefore, HE may be a potent anti-PD drug that can re-
duce neuroinflammation, neurodegeneration, and α-
synucleinopathy.
Additional file
Additional file 1: Hypoestoxide reduces human α-synuclein
accumulation in a mouse model of PD. Mice brain sections were
inmmunostained against human α-synuclein (Syn211 antibody) or C-terminal
of human α-synuclein (Syn105 antibody). a Immunofluorescence analysis of
human α-synuclein in the frontal cortex of non-tg and α-syn-tg mice treated
with either vehicle or hypoestoxide. (n = 5 per group; unpaired t test;
*p < 0.05). Error bars represent ± SEM. b Fluorescence intensity against
human α-synuclein was analyzed in frontal cortex of the brains. c
Immunohistochemical analysis of C-terminal of human α-synuclein in
the frontal cortex of non-tg and α-syn-tg mice. d Optical density
analysis for C-terminal of α-synuclein in frontal cortex. (n = 5 per
group; unpaired t test; **p < 0.01). Error bars represent ± SEM. Scale
bars = 250 μm (low magnification) and 25 μm (high magnification).
(TIF 13692 kb)
Fig. 5 Hypoestoxide inhibits NF-κB signaling in a mouse model of PD. a Representative immunohistochemical staining of NF-κB and phosphorylated
NF-κB in the neocortex of non-tg and α-syn-tg mice treated with either vehicle or hypoestoxide. b, c Fluorescence intensities against NF-κB (b) and
phosphorylated NF-κB (c) were analyzed in the neocortex of the brains (n = 5 per each group; two-way ANOVA, Bonferroni’s multiple
comparison post-test; ***p < 0.001). Error bars represent ±SEM. d Western blot analysis of cytosolic and nuclear fractions from the neocortex
for NF-κB and phosphorylated NF-κB. e The relative cytosolic phosphorylated NF-κB levels normalized against cytosolic total NF-κB. f The
relative nuclear phosphorylated NF-κB levels normalized against total nuclear NF-κB (n = 5 per each group; two-way ANOVA, Bonferroni’s
multiple comparison post-test; **p < 0.01, ***p < 0.001). Error bars represent ±SEM. Scale bar = 20 μm
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